Letrozole PCOS Infertility Treatment: A Complete Guide to Protocols, Monitoring and Next Steps

Letrozole PCOS infertility treatment is the use of an oral aromatase inhibitor, letrozole, to stimulate ovulation in women with polycystic ovary syndrome whose cycles are irregular or absent. Taken for five days early in the menstrual cycle, letrozole temporarily lowers oestrogen levels, prompting the pituitary gland to release more follicle-stimulating hormone (FSH) and trigger the growth of one or more follicles. It is now the internationally recommended first-line medication for anovulatory infertility in PCOS, having replaced clomiphene citrate in most clinical guidelines.

PCOS (polycystic ovary syndrome) is a hormonal disorder affecting roughly one in ten women of reproductive age. Its hallmarks are elevated androgens (male hormones), irregular or absent ovulation, and multiple small follicles visible on ultrasound. Because ovulatory dysfunction is the primary cause of infertility in PCOS, a medication that reliably restores ovulation is the logical starting point. According to a 2025 Italian guideline in Reproductive Biology and Endocrinology, correct therapeutic management of PCOS can allow long-term fecundability similar to or slightly higher than that of women without the condition.

PCOS disrupts fertility primarily by preventing regular ovulation. Without a mature egg being released each month, conception cannot occur naturally, and cycles may arrive weeks apart or not at all. The hormonal environment in PCOS, characterised by elevated LH, elevated androgens and often elevated insulin, creates a follicular arrest: many small follicles begin to develop but none reaches the size needed to trigger ovulation.

Insulin resistance is common in women with PCOS and amplifies the hormonal imbalance by stimulating the ovaries to produce more androgens. This is why lifestyle measures and medications such as metformin are often recommended alongside ovulation induction. A 2025 review confirms that ovulatory dysfunction is the main cause of infertility in PCOS and that it is highly treatable when managed systematically.

Beyond the physical effects, PCOS carries a significant psychological burden. Women with the condition have a measurably higher prevalence of anxiety and depression than the general population, and the uncertainty of irregular cycles can compound this stress. Understanding the hormonal picture is the first step toward a treatment plan that addresses both the physical and emotional dimensions of PCOS.

Letrozole is preferred over clomiphene citrate as the first medication tried for ovulation induction in PCOS because it produces higher pregnancy rates and live birth rates. The 2023 International PCOS Guideline, summarised in Fertility and Sterility, recommends letrozole as the first-line pharmacological treatment for infertile anovulatory women with PCOS, and recommends it rather than clomiphene citrate to improve ovulation, clinical pregnancy and live birth rates.

The mechanism explains the advantage. Letrozole blocks the enzyme aromatase, which converts androgens into oestrogen. The resulting temporary drop in oestrogen removes the negative feedback on the hypothalamus and pituitary, causing a surge in FSH that stimulates follicle growth. Because the effect is short-lived and oestrogen levels recover quickly after the tablets are stopped, the uterine lining (endometrium) develops normally. Clomiphene, by contrast, blocks oestrogen receptors for longer, which can thin the endometrium and reduce implantation rates even when ovulation occurs.

Letrozole also tends to produce mono-follicular development, meaning one dominant follicle rather than several, which keeps the risk of twins or higher-order multiples low. For women with PCOS who are already prone to an exaggerated ovarian response, this is a meaningful safety advantage.

Letrozole PCOS infertility treatment is suitable for women with PCOS-related anovulatory infertility who have no other significant cause of infertility identified, such as blocked tubes or severe male-factor issues. It is also indicated for women who have already tried clomiphene citrate and failed to ovulate (clomiphene resistance), and it can be used alongside metformin in women with insulin resistance. According to the 2025 review, suitability should be confirmed by a specialist after a full fertility assessment.

Before starting letrozole, your consultant will typically arrange baseline investigations: a pelvic ultrasound to assess the ovaries and uterus, a hormone profile including FSH, LH, AMH (anti-Müllerian hormone, a marker of ovarian reserve), thyroid function and prolactin, and a semen analysis for your partner. Ovarian reserve testing is particularly relevant in PCOS because AMH is often elevated, reflecting the large pool of small follicles, but this does not mean egg quality is automatically high.

Letrozole is not appropriate where there is a structural problem preventing conception, such as significant tubal damage or uterine abnormality, or where male-factor infertility is severe enough to require assisted conception from the outset. In those situations, the team at Jananam will discuss whether IUI or IVF is the more appropriate starting point.

A letrozole PCOS infertility treatment protocol begins with a specialist consultation to confirm the diagnosis, review baseline investigations and rule out other causes of infertility. Once the plan is agreed, letrozole is started on cycle day 2 or 3 and taken once daily for five consecutive days. According to the 2025 review, the starting dose is typically 2.5 mg daily, with escalation to 5 mg and then 7.5 mg in subsequent cycles if ovulation does not occur at the lower dose.

Around cycle day 10–12, a transvaginal ultrasound scan is performed to measure follicle size and endometrial thickness. When the lead follicle reaches approximately 18–20 mm in diameter, an ovulation trigger injection (usually hCG, human chorionic gonadotropin) may be given to time ovulation precisely. Timed intercourse or intrauterine insemination (IUI) is then planned for 36–40 hours after the trigger.

After ovulation is confirmed, progesterone support may be prescribed to strengthen the luteal phase. A pregnancy test is performed approximately 14 days after ovulation. If the cycle is unsuccessful, the consultant reviews the response, adjusts the dose if needed, and plans the next attempt. The 2025 Italian guideline advises completing 6–12 ovulatory cycles before moving to IUI or IVF, and about 6 cycles for women over 35. Your consultant will set the plan for you.

• Cycle Day: Day 1 · Action: Period begins; contact clinic · Purpose: Confirm cycle start
• Cycle Day: Day 2–3 · Action: Begin letrozole (2.5–7.5 mg daily for 5 days) · Purpose: Stimulate follicle growth
• Cycle Day: Day 10–12 · Action: Transvaginal ultrasound scan · Purpose: Measure follicle size and endometrial thickness
• Cycle Day: Day 12–14 (approx.) · Action: hCG trigger injection if follicle is 18–20 mm · Purpose: Time ovulation precisely
• Cycle Day: Day 14–16 (approx.) · Action: Timed intercourse or IUI · Purpose: Maximise chance of fertilisation
• Cycle Day: Day 21 (approx.) · Action: Progesterone blood test or luteal support · Purpose: Confirm ovulation; support implantation
• Cycle Day: Day 28–30 (approx.) · Action: Pregnancy test · Purpose: Assess outcome

Ultrasound follicular tracking is essential during every letrozole PCOS infertility treatment cycle. It confirms that at least one follicle is growing, measures the endometrial lining, and identifies the right moment to trigger ovulation or time intercourse. According to the 2025 review, monitoring also aims to detect excessive multi-follicular growth early, so that the cycle can be cancelled or converted to IVF if the risk of multiple pregnancy becomes unacceptable.

Endometrial assessment is equally important. A lining of at least 7 mm with a trilaminar (triple-layer) appearance on ultrasound is generally considered adequate for implantation. If the lining is thin despite good follicular growth, your consultant may adjust the protocol or investigate further.

Ovulation can be confirmed after the event by a mid-luteal progesterone blood test, taken around seven days after the expected ovulation date. A progesterone level above your laboratory's ovulation threshold indicates that ovulation has occurred. Combining ultrasound tracking with a progesterone check gives the clearest picture of whether the cycle has worked as intended. Women with unexplained infertility who are also being investigated alongside PCOS will find this monitoring particularly informative.

When letrozole PCOS infertility treatment fails to produce ovulation at the maximum dose of 7.5 mg, or when ovulation occurs but pregnancy does not follow after several cycles, the next steps are considered in a stepwise fashion. Letrozole resistance is defined as failure to ovulate at 7.5 mg daily for five days. In one single-centre study reported in a 2024 abstract in Human Reproduction, about 2.7% of infertile women with PCOS (50 of 1,851) did not ovulate even at 10 mg daily. For these women, and for those who ovulate but do not conceive, a range of escalation options exists.

The first escalation is often the addition of low-dose gonadotropins (injectable FSH or LH/FSH combinations) to the letrozole cycle, providing a stronger stimulus to the ovaries while still aiming for mono-follicular development. This combination is monitored closely with serial ultrasound scans. If gonadotropins alone are insufficient, laparoscopic ovarian drilling (LOD) is a surgical option that destroys a small amount of androgen-producing ovarian tissue, which can restore spontaneous ovulation in some women.

Where these measures do not succeed, or where additional factors such as tubal disease, endometriosis, or significant sperm DNA fragmentation are present, IUI or IVF with ICSI becomes the recommended path. IVF allows the team to retrieve multiple eggs, fertilise them in the laboratory, and select the best embryo for transfer, bypassing the ovulation step entirely. For women with PCOS who are at elevated risk of OHSS during IVF stimulation, a freeze-all strategy, where all embryos are frozen and transferred in a subsequent natural or medicated cycle, significantly reduces that risk.

• Stage: First line · Intervention: Letrozole 2.5–7.5 mg for 5 days · Typical indication: Anovulatory PCOS, no other infertility factors
• Stage: Second line · Intervention: Letrozole plus low-dose gonadotropins · Typical indication: No ovulation at 7.5 mg or poor follicular response
• Stage: Second line (surgical) · Intervention: Laparoscopic ovarian drilling · Typical indication: Letrozole resistance, suitable anatomy
• Stage: Third line · Intervention: IUI with ovarian stimulation · Typical indication: Ovulation achieved but no pregnancy after about 6 or more ovulatory cycles
• Stage: Third line / advanced · Intervention: IVF with ICSI · Typical indication: Tubal factor, male factor, failed IUI, complex PCOS

Jananam is a single-speciality fertility clinic in Neelankarai, Chennai, focused exclusively on the investigation and treatment of infertility. Because the clinic treats only fertility cases, every protocol, every scan and every laboratory process is designed around reproductive outcomes rather than being shared with a broader gynaecology or obstetrics service. The team's consultants bring over two decades of combined experience in reproductive medicine, and that depth of experience matters most in complex PCOS cases where the response to letrozole is unpredictable.

For women with PCOS who progress to IVF, Jananam's Certified Cleanroom Lab provides a tightly controlled environment for egg collection, fertilisation and embryo culture. Temperature, air quality, humidity and light exposure are all regulated to standards that protect embryo development. This is particularly relevant for women with low AMH or poor ovarian reserve, where every egg retrieved carries greater weight, but it benefits all IVF patients by maintaining consistent laboratory conditions cycle after cycle.

The clinic's approach to letrozole PCOS infertility treatment is individualised from the first consultation. Your consultant will review your hormone profile, ultrasound findings, partner's semen analysis and any previous treatment history before recommending a starting dose and monitoring schedule. If you have already tried letrozole elsewhere without success, the team will assess whether the protocol was optimised, whether additional investigations are needed, and whether a different pathway is more appropriate for your specific situation. You can read more about the clinic's philosophy on the why choose Jananam page.

The emotional weight of fertility treatment is real and should be taken seriously alongside the medical plan. An expert-opinion paper in Clinical Endocrinology lists poor mental health among the features of PCOS, and the 2025 Italian guideline recommends that infertile women with PCOS are screened for depression and anxiety during psychological counselling as part of the infertility work-up.

Multiple letrozole cycles without a positive result can be particularly draining. Each two-week wait carries hope, and each negative test carries disappointment. It is normal to feel grief, frustration or isolation, and these feelings do not reflect weakness or a lack of resilience. Acknowledging them is the first step toward managing them.

At Jananam, emotional support is woven into the treatment process rather than treated as an optional extra. Your consultant and the wider team are available to discuss not just the clinical picture but how you are coping with the process. If more structured support is needed, referral to a counsellor with experience in fertility-related distress can be arranged. Couples are encouraged to attend consultations together wherever possible, so that both partners feel informed and supported at each decision point.